• oakey66@lemmy.world
    link
    fedilink
    English
    arrow-up
    5
    arrow-down
    51
    ·
    11 months ago

    Personalized medicine is a way to rob you blind. Drugs cost unreal money. So does the hospital administration.

    • beckerist@lemmy.world
      link
      fedilink
      English
      arrow-up
      74
      arrow-down
      2
      ·
      11 months ago

      The first human reference genome to be sequenced cost over 3 Billion dollars. Today you can send some spit to a lab and have your own genome sequenced for less than $500.

      • oakey66@lemmy.world
        link
        fedilink
        English
        arrow-up
        11
        arrow-down
        1
        ·
        11 months ago

        I worked for one the first hospitals that was doing genomic testing for oncology patients in the U.S. I am not advocating against genomic testing or precision medicine, but Amerisource Bergen, (at the time) McKesson, and the sales people at the manufacturer were licking their chops at the thought of precision medicine. It was extremely lucrative for some improvements on QoL. I sincerely hope that it’s not cost prohibitive to patients and results in breakthroughs in treatment. But I did watch as a lung cancer drug was administered to patients at the cost of 250k per treatment. I don’t remember how many treatments there were but the cost was insane. The US system of healthcare is absolutely broken and I believe there’s a study that particularly evaluated cancer as a major cause of families depleting whatever savings they had within a couple years of being diagnosed. This is an indictment of the whole system. Not the efficacy of the drugs.

      • sudoshakes@reddthat.com
        link
        fedilink
        English
        arrow-up
        21
        ·
        11 months ago

        Most modern cancer drug treatment is sequenced to at least the specific proteins of the type of cancer it is.

        Have breast cancer? Cool. We figure out which of the many variations so that we can give you medications for that exact type of breast cancer.

        This sort of specific targeting has been increasing and increasing for the last 20 years. MRNA is the next step of that and is highly likely to be a means or become or for treatments in many other areas.